Pedro Marques Ramos
Overview
Explore the profile of Pedro Marques Ramos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeidan A, Ando K, Rauzy O, Turgut M, Wang M, Cairoli R, et al.
Lancet Haematol
. 2023 Dec;
11(1):e38-e50.
PMID: 38065203
Background: Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells. In this trial, we compared the...
2.
Ramos P, Choi J, Campbell C, Wang Y, Pallaud C, Dickinson M, et al.
EJHaem
. 2023 Aug;
4(3):876-881.
PMID: 37601870
Eltrombopag has been previously shown to be effective in reversing azacitidine-mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus...
3.
Okoye-Okafor U, Javarappa K, Tsallos D, Saad J, Yang D, Zhang C, et al.
J Exp Med
. 2022 Sep;
219(11).
PMID: 36053753
Thrombocytopenia, prevalent in the majority of patients with myeloid malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), is an independent adverse prognostic factor. Azacitidine (AZA), a mainstay...
4.
Zilli F, Ramos P, Auf der Maur P, Jehanno C, Sethi A, Coissieux M, et al.
EMBO Mol Med
. 2021 Mar;
13(4):e13162.
PMID: 33751828
Metastasis is the main cause of deaths related to solid cancers. Active transcriptional programmes are known to regulate the metastatic cascade but the molecular determinants of metastatic colonization remain elusive....
5.
Bruck O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, et al.
Blood Adv
. 2020 Jan;
4(2):274-286.
PMID: 31968078
The immunologic microenvironment in various solid tumors is aberrant and correlates with clinical survival. Here, we present a comprehensive analysis of the immune environment of acute myeloid leukemia (AML) bone...
6.
Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella M, et al.
Blood
. 2018 Oct;
132(25):2629-2638.
PMID: 30305280
Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled...